| Insulin Glargine | Insulin Degludec | |
|---|---|---|
| What it is | Insulin (diabetes) | Insulin (diabetes) |
| Used for | ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatri… | is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. Limitations of Use • Not recommended for the treatment of diabetic ketoacidosis. TRESIBA is a long-acting human insulin analog indicated to improve glycemic co… |
| Usual adult dose | Not on the label | In adults, inject subcutaneously once daily at any time of day. |
| Children | ? The safety and effectiveness of BASAGLAR have been established in pediatric patients (age 6 to 15 years) with type 1 diabetes based on an adequate and well-controlled trial of another insulin glargine product, 100 units/mL, in pediatric patients (age 6 to 15… | For pediatric patients requiring less than 5 units of TRESIBA each day, use a TRESIBA U-100 vial. |
| Prescription (U.S.) | Yes | Yes |
| Common side effects | The following adverse reactions are discussed elsewhere: Hypoglycemia [see Warnings and Precautions ( 5.3 )] . Hypoglycemia Due to Medication Errors [see Warnings and Precautions ( 5.4 )] . Hypersensitivity Reactions [see Warnings… | The following adverse reactions are also discussed elsewhere: • Hypoglycemia [see Warnings and Precautions ( 5.3 )] • Hypoglycemia due to Medication errors [see Warnings and Precautions ( 5.4 )] • Hypersensitivity reactions [see W… |
| Pregnancy | 8.1 Pregnancy Risk Summary Published studies with use of insulin glargine products during pregnancy have not reported a clear association with insulin glargine products and adverse developmental outco… | 8.1 Pregnancy Risk Summary Available data from one unpublished trial and the published literature with TRESIBA use during pregnancy have not identified a drug-associated risk of major birth defects, m… |
From the official U.S. labels. Brands and strengths differ between countries.
Neither official label mentions the other. That does not prove they are safe together: ask a pharmacist, and use the free interaction checker.
Check them togetherInsulin Glargine is insulin (diabetes) and Insulin Degludec is insulin (diabetes). Insulin Glargine is used for: ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatri… Insulin Degludec is used for: is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. Limitations of Use • Not recommended for the treatment of diabetic ketoacidosis. TRESIBA is a long-acting human insulin analog indicated to improve glycemic co…
Neither official label mentions the other. That does not prove they are safe together: ask a pharmacist, and use the free interaction checker.
It depends on what you are treating, your health and other medicines. Your doctor or pharmacist can tell you which one suits you; this page shows what each official label says.